Sonic Healthcare plummets following earnings downgrade
Shares in global pathology and radiology group Sonic Healthcare (ASX:SHL) fell more than 11% after the company turned an earlier earnings nudge into a full-blown downgrade.
Read MoreTag: SHL
Sonic Healthcare lifts dividend despite sharp drop in Covid-related earnings
Sonic Healthcare (ASX:SHL) has increased its dividend despite significant declines in earnings during the first half of December, triggered by the easing of the Covid pandemic.
Read MoreCompanies immune from rate rises: Sonic Healthcare, Cochlear, Transurban
Fund Manager Chris Pedersen discusses the RBA's rate hike, inflation, banks, dividend growth stocks, Sonic Healthcare, Transurban Group and Cochlear.
Read MoreSonic Healthcare (ASX:SHL) expands presence in Switzerland
Sonic Healthcare has announced its acquisition of Swiss laboratory network Synlab Suisse for CHF100m ($250.9m).
Read More3 Companies IML Is Backing Whichever Way the Wind Blows
In times like this, with heightened volatility and uncertainty, IML’s Bruce Du suggests three quality companies better placed to ride out the rough weather.
Read MoreMarket Murmurs: WOR, SHL, APA
The local earnings season rolled along Wednesday in a slightly happier environment for all concerned – here’s what Worley Group, Sonic Healthcare and APA Group had to say.
Read MoreSHL – Credit Suisse rates the stock as Outperform
The broker reduces the target to $39 from $40 and retains an Outperform rating.
Read MoreSHL – Morgans rates the stock as Hold
Morgans lowers its rating to Hold from Add and slashes its target price to $39.93 from $50.72.
Read MoreMarket Morsels: ADH, SUL, SHL, A2M
Pandemic-related damage popped up in a couple of interims from retail groups on Monday, while Sonic Healthcare’s good run may just be petering out and A2 Milk’s luck about to turn.
Read MoreSHL – Macquarie rates the stock as Neutral
The target price for Sonic Healthcare rises to $42.40 from $42.25 and the Neutral rating is maintained.
Read MoreCorporate Chit-Chat: BSL; SHL
Plenty of news from the AGMs of steelmaker BlueScope and pathology giant Sonic Healthcare, with guidance and trading updates provided at each. Here are the salient points.
Read MoreSHL – Credit Suisse rates the stock as Outperform
Outperform retained. Target rises to $46.50 from $45.00.
Read MoreSHL – Morgans rates the stock as Add
While covid uncertainty is likely to continue to cloud the near and medium term, Morgans believes there will likely be continued organic growth and retains its Add rating. The target price increases to $45.98 from $36.15.
Read MoreSonic Rides Delta to Record Sales
More Covid tests meant more money for Sonic Healthcare in the year to June 30, with the pathology group arguably the single biggest beneficiary of the pandemic on the ASX.
Read MoreSHL – Credit Suisse rates the stock as Outperform
Credit Suisse maintains an Outperform rating and $40 target and expects more than a -$1bn reduction in net debt in FY21.
Read MoreCashflows Stay Strong During COVID-19
The positive results from core shareholdings for 2021 FY reiterate why Investors Mutual invests in good quality, well-established businesses which produce real cashflows, earnings, and dividends.
Read MoreCOVID a Tonic For CSL, Sonic
COVID has been good news for two of Australia’s health giants – Sonic Healthcare and CSL which both revealed very strong double-digit profits on Thursday for the six months to December.
Read MoreSHL – Credit Suisse rates the stock as Outperform
Testing rates for coronavirus have rapidly expanded in the US and Europe. Sonic Healthcare has around 70% earnings exposure to the northern hemisphere, Credit Suisse points out.
Read MoreVirus Testing Demand Swells Sonic Bottom Line
COVID-19 has been kind to the pathology group, Sonic Healthcare, in fact, it’s been a boon judging by the company’s first-quarter performance. But the question is for how long? Is testing going to continue, become seasonal, or as we get on top of it fade away?
Read MoreSHL – UBS rates the stock as Upgrade to Neutral from Sell
On calculating the contribution of coronavirus testing to the company’s financial performance, UBS makes material upgrades over the short term.
Read MoreSHL – UBS rates the stock as Sell
UBS forecasts revenue growth of 10% for Sonic Healthcare in FY20, mostly driven by pathology in the second half. Earnings for the year are expected to be down -7% versus last year.
Read MoreSHL – UBS rates the stock as Sell
Analysis of Sonic Healthcare’s contribution to virus testing leads the broker to upgrade its revenue assumptions for FY21. The broker assumes a reduction in routine pathology earnings will be fully offset by increased testing earnings, and total earnings may well be above pre-virus levels.
Read MoreSHL – Credit Suisse rates the stock as Outperform
As testing for the coronavirus rapidly rises in key markets Credit Suisse models the revenue and earnings opportunity.
Read MoreRecovery Underway For Sonic Healthcare
The main issue confronting Sonic Healthcare is how quickly routine pathology testing recovers, given temporary government support is underpinning COVID-19 volumes.
Read MoreSonic Healthcare Shares Move Higher On Reinstated Guidance
Pathology giant Sonic Healthcare has come through the pandemic and lockdowns in good shape, reinstating 2019-20 earnings guidance yesterday and seeing its shares enjoy a 4.7% gain to $30.33.
Read MoreSHL – Citi rates the stock as Buy
Citi assesses the potential value of the US market for pandemic testing at US$6bn the six months ending December 2020.
Read MoreSHL – UBS rates the stock as Sell
UBS is concerned about the ongoing focus on test pricing and growth in outlays and what this means for healthcare budgets.
Read MoreCould Coronavirus Benefit Sonic Healthcare?
The share price of Sonic Healthcare (ASX:SHL) has not been immune to the recent market sell-off. However, they have outperformed the S&P/ASX 200 Index as well as the S&P/ASX Healthcare over the past three weeks.
Read MoreSHL – UBS rates the stock as Sell
Sonic Healthcare’s earnings fell slightly short of UBS estimates despite a beat on revenue thanks to a solid contribution from Aurora.
Read MoreSHL – Credit Suisse rates the stock as Neutral
Going into the first half result, due February 19, Credit Suisse envisages low risk to FY20 guidance.
Read MoreSHL – Deutsche Bank rates the stock as Hold
Sonic Healthcare has sold its 85% stake in GLP Systems. Deutsche Bank retains its Hold rating while lifting the price target to $26.32 (was $24.70).
Read MoreSonic Health Exits German Lab Business
Sonic Healthcare has bailed out of the German healthcare sector by selling its majority stake a German automated laboratory system business for $130 million.
Read MoreSHL – Morgans rates the stock as Add
Sonic Healthcare’s first-half result beat the broker, the company reporting strong organic cash flow and cash conversion of 101%.
Read MoreSonic Healthcare Expands With US Pathology Deal
Sonic Healthcare is raising $600 million in an accelerated placement to big shareholders and plans to ask small shareholders for another $100 million to help pay for its $750 million purchase of US group Aurora Diagnostics.
Read MoreEurope Unit Sees Sonic Reaffirm Outlook
Primary Healthcare’s (PRY) rival, Sonic Healthcare (SHL) had better news for shareholders and the market yesterday in its first half report.
Read MoreSonic Lowers Earnings Outlook
Healthcare has been one of the better areas for local investors in the past year, but suddenly there are shoals ahead with a couple of surprise earnings downgrades emerging from major operators in the past week.
Read MoreSonic Joins The Downgraders
Sonic Healthcare (SHL) yesterday joined the growing list of companies downgrading either their interim or full year profits and saw its shares sold off by nervy investors.
Read MoreOpportunities In An Ageing Population
An ageing population is a major demographic and economic issue affecting most advanced economies around the world and Australia is no exception. In today’s Investing Report, we highlight eight stocks we believe are best placed to benefit.
Read MoreSonic Down Despite Higher Profit, Dividend
Sonic Healthcare (SHL), the local and international diagnostics group, reported a near 15% rise in full year net profit after tax to $385 million, thanks to strong growth in its Australian and European pathology operations.
Read MoreSonic Posts A Healthy Lift In Global Profit
Medical diagnostics company, Sonic Healthcare (SHL) reported strong double digit earning and profit growth in the first half of the 2014. Sonic’s net profit grew by 17.7% to $177.3 million.
Read More
